

INSTITUTIONAL BIOSAFETY COMMITTEE MEETING DRAFT MINUTES

The University of Texas at San Antonio
Wednesday July 1, 2026
Microsoft Teams Meeting

Minutes Prepared by: Yulissa E. Stevens

MEMBERS PRESENT (7 needed for quorum)

- ☒ Dr. Jose Lopez-Ribot, Chair, Voting
- ☒ Dr. Janakiram Seshu, Vice-Chair, Voting
- ☒ Dr. JiehJuen Yu, Voting
- ☐ Dr. Karl Klose, Voting
- ☒ Dr. Marcel Perret-Gentil, Voting
- ☐ Dr. Jurgen Engelberth, Voting, Plant Specialist
- ☒ Dr. Astrid Cardona, Voting
- ☐ Mr. Rich Garza, Asst. Director Laboratory Safety & Hazardous Materials Management with vote
- ☒ Ms. Yolanda Acosta, *ex officio* Scientific Alternate with vote
- ☐ Dr. Ana Vallor, Non-Affiliated, Voting
- ☐ Dr. Shannan Hall-Ursone, Non-Affiliated, Voting
- ☒ Mr. Anthony Vallejo, *ex officio*, Director of Laboratory Safety, (Scientific Alternate)

GUESTS

- ☒ Mrs. Rachel Davis, UTSA Scholarly Resources Librarian
- ☐ Ms. Jolyn Demarest, Occupational Health Program non-voting
- ☐ Dr. Hamid Badali, Voting, (Scientific Alternate)
- ☒ Ms. Yulissa Stevens, Laboratory Safety Specialist non-voting

START: 9:02AM

ADJOURN: 9:29AM

7 voting members present

I. Review of the Minutes of the Previous IBC Meeting

Review of the March 4th Minutes – Approved

Committee Decision: 8 in favor, 0 opposed, and 0 abstention

II. Review of New or Renewal Applications

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC#2086: Investigate the catalytic mechanisms of the enzymes involved in roseoflavin biosynthesis

Project Overview

Microbial Agents, Infectious Agents or Toxins
Minimal nonpathogenic bacterial strains are used exclusively
Biosafety Level
BSL-1
Risk Group
RG 1
Section of the NIH Guidelines (if applicable)
Section III-F-8
Principal Investigator
Audrey Lamb

Committee Decision: 7 in favor, 0 opposed, and 0 abstention

Score: 01

IBC# 2082 Regulation of gene expression be chromatin compaction

Project Overview

Microbial Agents, Infectious Agents or Toxins
E. coli NEB Stable, pWPI (lentiviral vector, 3rd generation), pAAV (adeno-associated virus)
Biosafety Level
BSL-2
Risk Group
RG 1
Section of the NIH Guidelines (if applicable)
III-D-3-a
Principal Investigator
Alexey Soshnev

Score: 01

Committee Decision: 7 in favor, 0 opposed, and 0 abstention

IBC#2084 Pathogenesis of Coxiella burnetii and vaccine-induced immunity against Q fever

Project Overview

Microbial Agents, Infectious Agents or Toxins
RG3: Coxiella burnetii (select agent) Strains: Nine Mile Phase I (C; lone 7, RSA 493), Nine Mile Crazy RSA514, Henzerling RSA331, Priscilla Q 177, Scurry Q 217 and KO Q 229 2) Orientia tsutsugamushi, Strains: Kato (VR-609. ATCC), Karp, Gilliam and Ikeda strains will be transferred from the Naval Medical Research Command (NMRC) to Zhang lab as needed for the potential research projects. RG2: Coxiella burnetii Nine Mile phase II (Clone 4, RSA 439) E. Coli BL20, Salmonella species, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia and Acinetobacter baumannii
Biosafety Level
BSL-3
Risk Group
RG2/RG3
Section of the NIH Guidelines (if applicable)
N/A
Principal Investigator
Quoquan Zhang

Score: 02

Committee Decision: 5 in favor, 2 opposed, and 0 abstention

III. Review of Amendments

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC#

Project Overview

S/N	Amendments	Reviewer comments	Decision
1	N/A	N/A	N/A

Score

Committee Decision: 0 in favor, 0 opposed, and 0 abstention

IV. Administrative Approvals

S/N	Lab Name	Title	Reviewer comments	Decision
1	Drew Johnson	IBC# 6529: Bacteria Coliform using membrane filtration method	N/A	IBC Chair approved 6.5.26

V. Expired / Closed Protocols

None at this time.

VI. New Business

[REDACTED]

[REDACTED]

VII. Adjourn

The meeting was adjourned at 9:29 a.m. Next meeting will take place on Wednesday, August 5, 2026 at 9:00 am via Teams.



X

Jose Lopez-Ribot
IBC Chair